- The FDA issued a complete response letter (CRL) to Incyte Corporation INCY ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use for certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).
- The complete response letter states that the FDA cannot approve the application in its present form.
- The FDA acknowledged that the study submitted in the marketing application met its objective of bioequivalence based on area under the curve (AUC) parameters but identified additional requirements for approval.
- Incyte intends to meet with the FDA to determine the appropriate next steps.
- William Blair writes that from an immediate commercial perspective, the CRL has no near-term implications, nor does it impact Jakafi's assumptions through the current loss of exclusivity at the end of 2028.
- The analyst writes that the QD formulation does have additional patent protection beyond 2028, which could have helped extend the tail of the franchise into the 2030s, and fixed-dose combinations (FDCs) are the crucial long-term revenue driver.
- Though probably not insurmountable, the CRL is a blow to the LIMBER program, more so than the recent failure of the LIMBER-304 study.
- BET and ALK2 programs still have a significant clinical trial runway, hopefully providing sufficient time to address the issues.
- Suppose modifications are required to the extended-release formulation or additional clinical studies for QD ruxolitinib approval. In that case, it may delay the potential work on FDCs required to move into pivotal studies.
- Price Action: INCY shares are down 5.21% at $68.49 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
